VANDA PHARMACEUTICALS INC. Investment Income, Interest
VANDA PHARMACEUTICALS INC. (VNDA) reported Investment Income, Interest of $461.00 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-09.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2012-03-09
- VANDA PHARMACEUTICALS INC. investment income, interest for the quarter ending 2011-12-31 was $99.00K, a 30.28% decline year-over-year.
- VANDA PHARMACEUTICALS INC. investment income, interest for the quarter ending 2011-09-30 was $106.00K, a 32.05% decline year-over-year.
- VANDA PHARMACEUTICALS INC. investment income, interest for the quarter ending 2011-06-30 was $121.00K, a 40.70% increase year-over-year.
- VANDA PHARMACEUTICALS INC. investment income, interest for the quarter ending 2011-03-31 was $135.00K.
- VANDA PHARMACEUTICALS INC. investment income, interest for fiscal 2011 was $461.00K, a 6.96% increase from fiscal 2010.
- VANDA PHARMACEUTICALS INC. investment income, interest for fiscal 2010 was $431.00K, a 384.27% increase from fiscal 2009.
- VANDA PHARMACEUTICALS INC. investment income, interest for fiscal 2009 was $89.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2011-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-09 | $205.00K derived: sum of 2 quarters · filed 2012-03-09 | $326.00K derived: sum of 3 quarters · filed 2012-03-09 | $461.00K 10-K · filed 2012-03-09 |
| 2011-09-30 | $106.00K 10-Q · filed 2011-11-07 | $227.00K derived: sum of 2 quarters · filed 2011-11-07 | $362.00K 10-Q · filed 2011-11-07 | $504.00K derived: sum of 4 quarters · filed 2012-03-09 |
| 2011-06-30 | $121.00K 10-Q · filed 2011-08-05 | $256.00K 10-Q · filed 2011-08-05 | $398.00K derived: sum of 3 quarters · filed 2012-03-09 | $554.00K derived: sum of 4 quarters · filed 2012-03-09 |
| 2011-03-31 | $135.00K derived: 10-K 12 month − 3 quarters · filed 2012-03-09 | $277.00K derived: sum of 2 quarters · filed 2012-03-09 | $433.00K derived: sum of 3 quarters · filed 2012-03-09 | $519.00K derived: sum of 4 quarters · filed 2012-03-09 |
| 2010-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-09 | $298.00K derived: sum of 2 quarters · filed 2012-03-09 | $384.00K derived: sum of 3 quarters · filed 2012-03-09 | $431.00K 10-K · filed 2012-03-09 |
| 2010-09-30 | $156.00K 10-Q · filed 2011-11-07 | $242.00K derived: sum of 2 quarters · filed 2011-11-07 | $289.00K 10-Q · filed 2011-11-07 | |
| 2010-06-30 | $86.00K 10-Q · filed 2011-08-05 | $133.00K 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $89.00K 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |